Royal DSM, a global science-based company active in health, nutrition and materials, announces it has acquired BioCare Copenhagen A/S, based in Copenhagen (Denmark).
With the acquisition, DSM expands its offering in gut health ingredients with probiotics, an attractive market segment in nutritional ingredients, growing an estimated 7% per year. Financial details will not be disclosed at this time.
BioCare Copenhagen is a privately-held company founded in 2012, focused on probiotics and specialized in microbial actives with proven health benefits, targeting gastrointestinal disorders, metabolic disorders, infections, and immunity. The company offers high-quality white label probiotic supplements and complete product concepts with strong consumer appeal. BioCare Copenhagen has multi-market distribution agreements with a number of leading dietary supplements and pharmaceutical companies and has launched products in over 40 countries worldwide.
DSM already has a strong position in gut health solutions with its Culturelle® product range, the number-one-selling probiotic dietary supplement consumer brand globally, as well as with its ingredient brands Oatwell® and Tolerase®. The company sees further growth potential in gut health ingredients beyond the established indications for digestive health and immune health. Fields increasingly recognized as being impacted by the gut microbiome include the gut-brain axis, metabolic health and heart health. DSM’s ambition in addressing the gut microbiome and its portfolio of nutritional ingredients are very synergetic with BioCare Copenhagen’s approach and products, and the combination is well-catered to address the existing and emerging gut health areas.
Source: DSM
The company plans to pour more than $500 million in additional funds into its active pharmaceutical ingredient (API) plant in Raheen, Limerick County, the country’s Industrial Development Agency (IDA) said. The new funding brings the company’s total investment in the site to 927 million euros ($1 billion).
“If in 2005 someone told you that two-thirds of our industry would be driven on the R&D side by emerging biopharma—it would be unthinkable. If one were to project that trend forward, what it would suggest is that we could have a day when we do this talk, say in 2027 or 2028, where 80% of the industry’s pipeline is coming from emerging companies.”
The German healthcare and agrochemicals giant told Reuters that in future its pharma pipeline will focus on cardiovascular disease, neurology, rare diseases and immunology, while de-emphasizing women’s health, a field it first focused on with the acquisition of the former women’s health specialist Schering in 2006.